1. HBW Insight
  4. >>Regulation

Overhaul To Improve US OTC Monograph Program Could Steer Sponsors To NDA Process

 
• By Malcolm Spicer

Some would-be sponsors might opt against submitting OMORs because NDA process could offer more room for adjustments and a better chance for success. Absence of assurance in draft guidance of confidentiality for information sponsors share with FDA before submitting OMORs also could influence some to choose NDA process.

• Source: Shutterstock

The US drug industry may need to lower its expectations about the number and variety of additional OTC drug formulations and indications becoming available in the US through the Food and Drug Administration’s overhauled monograph program.

Food and drug attorneys pointed out during a recent Food and Drug Law Institute online conference that even with the program becoming more efficient and predictable under reform authorized by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation